<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22785" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hepatitis A</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Girish</surname>
            <given-names>Vishnu</given-names>
          </name>
          <aff>Institute of Liver and Biliary Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Grant</surname>
            <given-names>Lafaine M.</given-names>
          </name>
          <aff>University of Texas Southwestern Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>John</surname>
            <given-names>Savio</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vishnu Girish declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lafaine Grant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Savio John declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22785.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hepatitis A virus (HAV) infection is a globally significant public health issue, particularly prevalent in developing countries where sanitation practices may be inadequate. The virus primarily spreads through the oral-fecal route, causing acute hepatitis that can range from mild to severe, though it does not lead to chronic liver disease. Clinical manifestations of HAV vary widely, from asymptomatic cases to more severe presentations such as jaundice, cholestatic hepatitis, and, in rare cases, fulminant hepatitis. The incubation period is typically around 28 days, after which symptoms like jaundice, dark urine, and fatigue may appear. Most infections are self-limiting, but severe cases can result in acute liver failure, especially in older adults or those with preexisting liver conditions. Prevention through vaccination and proper sanitation remains the most effective strategy, as no specific antiviral treatment exists for HAV.</p>
        <p>Participants in this educational activity gain an in-depth understanding of the epidemiology, transmission, and clinical presentation of HAV infection, providing them with the knowledge to accurately diagnose and manage the condition. The course emphasizes the importance of vaccination and supportive care while highlighting the role of an interprofessional team in enhancing patient outcomes. By collaborating with specialists in infectious diseases, gastroenterology, and public health, healthcare professionals can ensure comprehensive care, address potential complications, and implement effective prevention strategies, ultimately improving patient care and public health outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the key risk factors and modes of transmission for Hepatitis A to effectively prevent and manage outbreaks.</p></list-item><list-item><p>Differentiate between the clinical presentations of hepatitis A virus infection and other forms of hepatitis to ensure accurate diagnosis and treatment.</p></list-item><list-item><p>Select the most effective supportive care strategies for managing hepatitis A virus infection, considering patient-specific factors and clinical presentation.</p></list-item><list-item><p>Collaborate with an interprofessional team, including public health officials, to design and implement community-based hepatitis A virus prevention programs.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22785&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22785">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22785.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The hepatitis A virus (HAV) is a common infectious etiology of acute hepatitis worldwide. HAV is most commonly transmitted through the fecal-oral route via exposure to contaminated food, water, or close physical contact with an infectious person. According to the World Health Organization, infection rates in&#x000a0;high-resource countries are low. However, high-risk groups include injected drug users, men who have sex with men, people traveling to endemic areas, and isolated communities.</p>
        <p>HAV does not cause chronic liver disease, unlike hepatitis B or C.<xref ref-type="bibr" rid="article-22785.r1">[1]</xref>&#x000a0;Acute HAV infection usually presents as a self-limited illness; the development of fulminant hepatitis is rare. Typical symptoms of acute infection include nausea, vomiting, abdominal pain, fatigue, malaise, poor appetite, and fever; management is with supportive care. Alternate clinical patterns include cholestatic, prolonged, and relapsing disease.</p>
        <p>Vaccination against HAV is recommended for children 12 months or older and adults with the risk of exposure, including travelers to endemic countries, men who have sex with men, people who use drugs (injected and non injected), potential occupational exposure, and chronic liver disease.<xref ref-type="bibr" rid="article-22785.r2">[2]</xref><xref ref-type="bibr" rid="article-22785.r3">[3]</xref><xref ref-type="bibr" rid="article-22785.r4">[4]</xref><xref ref-type="bibr" rid="article-22785.r5">[5]</xref>&#x000a0;Globally, the rates of HAV have decreased due to improvements in public healthcare policies, sanitation, and education, but infection rates of other hepatitis viruses appear to be increasing.</p>
      </sec>
      <sec id="article-22785.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>HAV is one of the most common causes of acute hepatitis infection worldwide.&#x000a0;The discovery of a virus-like antigen in 1973 via immune electron microscopy marked a pivotal advancement in comprehending acute infectious hepatitis, culminating in&#x000a0;identifying HAV.<xref ref-type="bibr" rid="article-22785.r6">[6]</xref>&#x000a0;Initially categorized as enterovirus type 72, HAV is now classified as the sole member of the <italic toggle="yes">Hepatovirus</italic> genus within Picornaviridae.<xref ref-type="bibr" rid="article-22785.r7">[7]</xref>&#x000a0;Despite sharing structural similarities with insect-infecting picornaviruses and having evolutionary roots in bats, rodents, and shrews, HAV exhibits distinctive features in its life cycle and hepatotropism.<xref ref-type="bibr" rid="article-22785.r8">[8]</xref>&#x000a0;</p>
        <p>This nonenveloped, icosahedral virus, measuring 27 to 32 nm, is transmitted fecal-orally and displays notable differences in its physical form when excreted versus circulating in the blood. Genomic analysis reveals 6 genotypes, 3 infecting humans and 3 found in primates. Genotype distribution varies geographically, with human infections predominantly involving genotype 1. The HAV genome, a 7.5 kb positive-sense single-stranded ribonucleic acid, contains an internal ribosome entry site, modified capsid proteins, and specific replication elements.&#x000a0;</p>
        <p>
<bold>Hepatitis A Risk Factors</bold>
</p>
        <p>Factors that increase an individual's risk of HAV infection include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Close personal contact with infected persons (eg, household members, caretakers, sexual partners)</p>
          </list-item>
          <list-item>
            <p>Close contact with international adoptees from high endemicity regions</p>
          </list-item>
          <list-item>
            <p>Occupational exposure (eg, laboratory workers and primate handlers)</p>
          </list-item>
          <list-item>
            <p>Injection and non injection drug use</p>
          </list-item>
          <list-item>
            <p>High-population group settings (eg, homeless shelters, syringe service programs, and correctional facilities)</p>
          </list-item>
          <list-item>
            <p>International travel to regions with high or intermediate HAV endemicity</p>
          </list-item>
        </list>
        <p>Additionally, risk factors for severe HAV disease include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Immunocompromised persons (eg, human immunodeficiency virus, chronic renal failure, transplant recipients, and those on immunosuppressive therapy),</p>
          </list-item>
          <list-item>
            <p>Chronic liver disease (eg, hepatitis B or C infection, cirrhosis, fatty liver disease, and elevated liver enzymes)</p>
          </list-item>
          <list-item>
            <p>Adults older than 40&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22785.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Improved sanitation has resulted in a shift in the age group that acquires hepatitis A, which has led to a decline in the incidence of new cases in recent years.&#x000a0;The United States has a low endemicity; however, Mexico has a high prevalence of individuals with anti-HAV antibodies, indicating a&#x000a0;previous infection. The frequency of acute hepatitis is higher in countries that are adjacent to Mexico. The reported hepatitis A incidence has declined by 90% to as low as 1.2 cases per 100,000 population, with the most significant reductions seen in children and countries where routine vaccination started in 1999.<xref ref-type="bibr" rid="article-22785.r9">[9]</xref>&#x000a0;</p>
        <p>Over the last 4 decades, the average age of hepatitis A-infected individuals has increased, and those in high-risk populations account for most cases of HAV infection.&#x000a0;The classification of HAV endemicity is based on the age-specific seroprevalence of anti-HAV immunoglobulin G (IgG). Age-associated seroprevalence surveys of anti-HAV IgG are essential for elucidating historical infection rates and population susceptibility. However, incidence studies relying on case reports are often faced with data incompleteness and bias.</p>
        <p>
<bold>Geographical Incidence and Transmission Patterns</bold>
</p>
        <p>Individuals in high-endemicity regions such as sub-Saharan Africa and certain parts of South Asia exhibit 90% or more anti-HAV IgG positivity by age 10. These areas experience low disease rates, with most infections occurring in early childhood (ie, younger than 5). Transmission is predominantly interpersonal, facilitated by inadequate sanitation.</p>
        <p>Patients in medium-endemicity areas, including Asia, Latin America, Eastern Europe, and the Middle East, demonstrate 50% or more seroprevalence by age 15 but less than 90% by age 10. These regions face high disease rates, affecting late childhood and young adulthood. Transmission occurs via person-to-person contact and through contaminated food and water sources during outbreaks.</p>
        <p>Economically advanced regions, including Western Europe, Australia, New Zealand, Canada, the United States, Japan, and Singapore, are&#x000a0;low endemicity areas with 50% or more seroprevalence by age 30 but less than 50% by age 15. These areas experience low disease rates, with infections primarily occurring in susceptible individuals. Transmission modes include interpersonal contact, food and water-related outbreaks, and travel-associated infections. Individuals in very low-endemicity regions (eg, Northern Europe) exhibit less than 50% seroprevalence by age 30. These areas experience low disease rates, with infections predominantly affecting susceptible individuals, similar to low-endemicity regions (CDC. Hepatitis A,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/hepatitis-a">https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/hepatitis-a</ext-link>).</p>
        <p>
<bold>Acute Liver Failure Incidence and&#x000a0;Hepatitis A Infection</bold>
</p>
        <p>In regions with low endemicity and developed settings, HAV contributes to less than 2% of acute liver failure (ALF) cases.<xref ref-type="bibr" rid="article-22785.r10">[10]</xref>&#x000a0;However, in medium and high endemicity regions, the incidence is highly variable, ranging from around 2% in some adult studies to approximately 30% in certain series.<xref ref-type="bibr" rid="article-22785.r11">[11]</xref><xref ref-type="bibr" rid="article-22785.r12">[12]</xref>&#x000a0;Recent observational studies from India indicate a concerning trend of symptomatic HAV infections in adolescents and adults, accompanied by an increased incidence of ALF and higher mortality rates among adolescents.</p>
        <p>
<bold>Age-Dependent Variations of Hepatitis A Infection</bold>
</p>
        <p>The clinical manifestations and outcomes of HAV infection exhibit significant age-dependent variations. In adults, symptomatic acute hepatitis A occurs in more than 70% of cases, with 3% to 20% experiencing relapsing or prolonged hepatitis.<xref ref-type="bibr" rid="article-22785.r13">[13]</xref>&#x000a0;ALF is rare, with less than 1% of adult cases, but when it does occur, approximately 30% may require liver transplantation. In contrast, children demonstrate a markedly different clinical profile, with fewer than 30% exhibiting symptomatic acute hepatitis A.</p>
        <p>Adults and children share a high spontaneous recovery rate exceeding 99%, underscoring the self-limiting nature of HAV infection. However, children generally experience a more benign course, rarely progressing to ALF or developing prolonged or relapsing hepatitis. Despite these age-related differences, the overall prognosis remains favorable for both groups with appropriate supportive care.&#x000a0;Most patients recover without significant medical intervention, although severe outcomes such as ALF and the need for liver transplantation are slightly more prevalent in adults.</p>
        <p>These age-dependent clinical patterns highlight the generally milder course of HAV infection in pediatric populations and emphasize the importance of age as a factor in predicting disease progression and outcomes.&#x000a0;The epidemiological impact of HAV is intricately linked to the average age of infection, with high-endemicity regions experiencing early, often asymptomatic infections in children. As incidence decreases and the average age of infection rises, more severe symptoms and increased healthcare costs are observed.&#x000a0;</p>
      </sec>
      <sec id="article-22785.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Following oral transmission, the virus enters the bloodstream from the gastrointestinal tract and is&#x000a0;carried to the basolateral membrane of the hepatocyte via the portal circulation.<xref ref-type="bibr" rid="article-22785.r7">[7]</xref>&#x000a0;HAV exhibits 2 infectious forms: naked, nonenveloped virions (nHAV) and quasi-enveloped virions (eHAV). The naked virions, characterized by a highly conserved antigenic structure, are shed in feces, while eHAV, a distinctive feature of HAV, is secreted from infected cells and found in blood. The dual nature of HAV virions plays a crucial role in its pathogenesis and transmission, highlighting the virus's adaptation to different host environments.&#x000a0;</p>
        <p>HAV infection of hepatocytes occurs via the HAV cellular receptor-1, also known as the T-cell immunoglobulin mucin domain-1 receptor, in the space of Disse. Results from recent studies suggest alternative entry pathways.<xref ref-type="bibr" rid="article-22785.r14">[14]</xref>&#x000a0;A complex interplay of innate and adaptive immune mechanisms characterizes the host response to HAV infection. HAV employs strategies to evade innate immunity, wherein the viral proteases target key signaling molecules and thereby suppress the type I interferon response. However, innate immunity is not completely evaded as the plasmacytoid dendritic cells produce significant type I interferons in response to HAV-infected cells or eHAV.<xref ref-type="bibr" rid="article-22785.r15">[15]</xref>&#x000a0;</p>
        <p>The adaptive immune response, particularly T-cell&#x02013;mediated immunity, appears crucial in viral clearance, potentially causing hepatocellular injury. While human studies have identified virus-specific cytotoxic CD8 T cells, results from recent research in chimpanzee models suggest a more prominent role for CD4 helper T cells in infection resolution.<xref ref-type="bibr" rid="article-22785.r16">[16]</xref><xref ref-type="bibr" rid="article-22785.r17">[17]</xref>&#x000a0;The dynamics of regulatory T cells during acute infection have also been implicated in the modulation of liver injury. Diagnosing acute hepatitis A primarily relies on detecting serum IgM antibodies to HAV or observing seroconversion in symptomatic individuals. Humans and primates exhibit delayed B-cell response due to the sequestration of viral antigens. A rapid, dominant, neutralizing IgG response targets conserved viral capsid protein epitopes, providing lifelong protection postinfection.&#x000a0;Passive immunization or postexposure vaccination within 2 weeks can prevent liver disease, likely through post-endocytic neutralization of eHAV. Multifunctional virus-specific CD4 T cells correlate with declining intrahepatic viral ribonucleic acid, indicating their primary role in controlling infection and interferon-stimulated genes.<xref ref-type="bibr" rid="article-22785.r18">[18]</xref>&#x000a0;</p>
        <p>Following replication in the liver, HAV is excreted in bile and released into the stool. The virus concentration is highest in the stool during the 2 weeks before the onset of jaundice, at which point the individual is most infectious (see <bold>Image</bold>. Hepatitis A&#x000a0;Replication Cycle).<xref ref-type="bibr" rid="article-22785.r19">[19]</xref>&#x000a0;Most people are no longer contagious 1 week after jaundice appears, at which time stool shedding and viremia are decreased.</p>
      </sec>
      <sec id="article-22785.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Liver biopsy is rarely performed in uncomplicated acute hepatitis A infections. When a biopsy is performed, histopathological examination reveals inflammation and necrosis in the periportal regions with varied levels of apoptosis.<xref ref-type="bibr" rid="article-22785.r20">[20]</xref><xref ref-type="bibr" rid="article-22785.r21">[21]</xref>&#x000a0;While cholestasis accompanied by an increased presence of plasma cells in the portal and periportal areas can be more indicative of hepatitis A, definitive diagnosis necessitates laboratory confirmation. In cases of severe hepatitis, necrotic bridges may form between portal areas.</p>
      </sec>
      <sec id="article-22785.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Hepatitis A Clinical Features</bold>
</p>
        <p>The following clinical presentations are frequently associated with HAV infection:</p>
        <list list-type="bullet">
          <list-item>
            <p>Asymptomatic infection</p>
          </list-item>
          <list-item>
            <p>Symptomatic infection with jaundice, dark urine, and clay-colored stool</p>
          </list-item>
          <list-item>
            <p>Cholestatic hepatitis with prolonged alkaline phosphatase and bilirubin elevation and pruritus</p>
          </list-item>
          <list-item>
            <p>Relapsing infection</p>
          </list-item>
          <list-item>
            <p>Fulminant hepatitis&#x000a0;<xref ref-type="bibr" rid="article-22785.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>HAV infection usually presents with an acute onset, similar to other hepatotropic virus infections, following an average incubation period of approximately 28 days (15-50 days).<xref ref-type="bibr" rid="article-22785.r22">[22]</xref>&#x000a0;The clinical course is characterized by initial prodromal symptoms, including malaise, vomiting, anorexia, fever, and right upper quadrant abdominal pain, followed by a more severe symptomatic phase. This phase, typically manifesting 1 week after the initial symptoms, may include fever, malaise, anorexia, nausea, abdominal discomfort, and jaundice, persisting for a median duration of 8 weeks.<xref ref-type="bibr" rid="article-22785.r23">[23]</xref>&#x000a0;</p>
        <p>The most prevalent symptoms include jaundice, observed in 40% to 80% of cases, and dark urine, reported by 68% to 94% of patients. Fatigue affects 52% to 91% of individuals, while loss of appetite or anorexia is noted in 42% to 90% of cases during the prodromal phase. Abdominal pain or discomfort is experienced by a third during the various stages.&#x000a0;Half&#x000a0;of the patients report cholestatic symptoms, including acholic stools.&#x000a0;The severity and manifestation of symptoms demonstrate a notable age-dependent pattern, with children younger than 6 years often presenting asymptomatically or with mild symptoms.&#x000a0;In contrast, older children and adults exhibit more pronounced symptomatology, including jaundice, in more than 70% of cases. Peak infectivity occurs 2 weeks before and at least 1 week following symptom onset. The acute illness typically resolves within 2 months, with a median duration of 2 weeks.&#x000a0;</p>
        <p>Physical examination reveals icterus and tender hepatomegaly. Acute HAV is associated with self-limiting pleural effusion, usually mild and undetected on examination.&#x000a0;In the cholestatic phase, scratch marks and shiny nails can be observed. Extrahepatic manifestations are rarely associated with splenomegaly, rash, lymphadenopathy, and arthritis. A high index of suspicion&#x000a0;must be kept for identifying hepatic encephalopathy and signs of coagulopathy, though it is a rare complication.&#x000a0;</p>
        <p>
<bold>Cholestatic hepatitis presentations</bold>
</p>
        <p>Marked by prolonged jaundice, cholestatic symptoms, including pruritus and acholic stools, with the labs showing elevated serum bilirubin and alkaline phosphatase levels, occur in less than 5% of patients. Cholestatic hepatitis&#x000a0;typically resolves spontaneously without sequelae. Rarely, patients with intractable pruritus might require specific therapy.</p>
        <p>
<bold>Relapsing infection presentations</bold>
</p>
        <p>Although HAV does not progress to a chronic stage or result in chronic viral shedding, cases of prolonged illness with recurrent symptoms or ALF have been documented and&#x000a0;affect up to 10% of patients, with episodes of relapse lasting up to 12 months. These protracted cases may involve delayed viral clearance, persistent symptoms, elevated liver enzymes, and severe cholestasis, with some instances of relapsing hepatitis and detectable HAV ribonucleic acid.</p>
        <p>Up to 10% of patients experience a relapse of symptoms within 6 months after the acute illness. Clinical relapse generally lasts less than 3 weeks, though biochemical relapse can persist for up to 12 months. The cause of relapsing hepatitis remains unknown, and no predisposing factors have been identified. Clinical relapse typically follows apparent recovery, with near normalization of serum aminotransferases, followed by biochemical and sometimes clinical relapse.</p>
        <p>Manifestations during relapse are often milder than the initial episode, but serum aminotransferases can exceed 1000 IU/dL, and serum anti-HAV IgM antibodies persist throughout the disease. HAV can be recovered from stool during relapses, indicating continued infectivity.&#x000a0;During relapses, extrahepatic manifestations such as arthritis, vasculitis, nephritis, and cryoglobulinemia have been reported.&#x000a0;Autoimmune hepatitis may be triggered by HAV infection in susceptible individuals, characterized by hyperglobulinemia, circulating autoantibodies, and inflammatory liver changes on histology, which might be another cause for this pattern.</p>
        <p><bold>Acute liver failure and fulminant hepatitis</bold>&#x000a0;<bold>presentations</bold></p>
        <p>Individuals with ALF and fulminant hepatitis frequently present with coagulopathy and altered sensorium after the onset of jaundice. The risk of ALF and mortality increases with age and preexisting liver conditions, with an overall case-fatality ratio of approximately 0.3%. Superinfection with HAV in patients with chronic hepatitis C can lead to severe outcomes, including ALF, and may trigger autoimmune mechanisms exacerbating liver damage. Coinfection with other viruses (eg, hepatitis G) has been observed, although the role of HAV in severe cases remains unclear.</p>
        <p>
<bold>Hepatitis A and Pregnancy</bold>
</p>
        <p>Acute HAV infection is associated with increased risks of preterm labor and gestational complications.<xref ref-type="bibr" rid="article-22785.r24">[24]</xref>&#x000a0;Extrahepatic manifestations, occurring in 10% to 15% of cases, include rash, arthralgias, leukocytoclastic vasculitis, arthritis, glomerulonephritis, cryoglobulinemia, optic neuritis, transverse myelitis, toxic epidermal necrolysis, myocarditis, thrombocytopenia, aplastic anemia, and red cell aplasia.<xref ref-type="bibr" rid="article-22785.r25">[25]</xref></p>
      </sec>
      <sec id="article-22785.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In patients presenting with the syndrome of acute hepatitis with characteristic clinical features as mentioned above, an HAV infection is suspected, and laboratory tests and exclusion of other conditions are necessary for the diagnosis. Biochemical parameters include a characteristic pattern in the liver function tests observed across various acute viral hepatitis presentations. Elevated bilirubin, serum aminotransferases, and alkaline phosphatase (ALP) are noted. The chronology of this derangement and the pattern of aminotransferase elevation are essential. Among the transaminases, the alanine aminotransferase level (ALT) is generally higher than in cases of other viral hepatitis and can rise 10- to 100-fold. Typically, the bilirubin level starts to increase later. Blood work usually reveals mild lymphocytosis and normal prothrombin time. If the prothrombin time becomes deranged, severe liver damage, including the risk for encephalopathy, should be suspected.</p>
        <p>Shortly after the ALT levels increase, HAV particles can be detected in the stool, though stool is not routinely tested. Anti-HAV IgM starts to rise after this, and the clinical symptoms appear shortly after the initial excretion of particles. When differential diagnoses are excluded, the presence of anti-HAV IgM and characteristic clinical features confirms the diagnosis of hepatitis A. Anti-HAV IgM usually remains positive for 4 to 6 months. Additional testing can include reverse transcriptase-polymerase chain reaction to detect viral ribonucleic acid, which can show false negative results in an acute infection. Anti-HAV IgG emerges soon after infection and remains&#x000a0;present for the person&#x02019;s lifetime.</p>
        <p>An abdominal ultrasound can help exclude other causes, including differentiating between extrahepatic and intrahepatic cholestasis and evaluating fever with abdominal pain. However, findings are frequently nonspecific (eg, gallbladder wall and periportal edema). Pleural effusion and perihepatic fluid are seen on rare occasions while visualizing the liver.</p>
        <p>Acute liver failure should be suspected in cases with deranged prolonged prothrombin time and monitoring for minimal hepatic encephalopathy. Close monitoring of prothrombin time and liver function tests are mandated. Signs of raised intracranial pressures (ICT) should be carefully monitored, as bradycardia, hypertension, and altered breathing patterns can indicate raised ICT. ICT can be monitored by transcranial Doppler, optic nerve sheath diameter, and reverse jugular monitoring. Moreover, a noncontrast computed tomography (CT) of the brain can demonstrate changes secondary to increased ICT. Deranged kidney function tests are a poor prognostic marker. Clinicians should also exclude sepsis. Evaluation and management are like any other case of ALF.</p>
        <p>In the cholestatic variant of hepatitis A infection,&#x000a0;ALP and gamma-glutamyl transferase are raised along with cholestatic symptoms, typical of intrahepatic cholestasis. Pruritus can be worrisome; testing of individuals with pruritus will typically have findings that show elevated bile acid levels. Usually, cholestasis does not persist long enough to cause a severe deficiency of fat-soluble vitamins.&#x000a0;</p>
      </sec>
      <sec id="article-22785.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Supportive Management</bold>
</p>
        <p>No specific treatment is needed for most patients with acute, uncomplicated HAV infection beyond supportive care. In individuals with fulminant hepatitis within regions where universal immunization is not possible, antiviral treatment would be helpful; this type of therapy is currently not available for HAV.&#x000a0;Cholestatic hepatitis A is also self-limiting; if pruritus is severe, antipruritic measures, including cholestyramine, rifampicin, or ondansetron, may be used. Refractory pruritus, though&#x000a0;a self-limiting condition, can rarely require plasma exchange.</p>
        <p>Severe HAV infections with ALF should be managed like other ALF cases. The Kings College criteria give a lower priority to ALF due to acute viral hepatitis as these are less severe. Despite the implementation of priority scoring systems like the Model for End-Stage Liver Disease (MELD) score or King&#x02019;s College criteria for liver transplantation referrals, it remains challenging to determine which patients with hepatitis A-associated ALF will need a transplant due to the lack of reliable biomarkers. However, Kings College criteria may not apply to high endemicity regions with higher prevalence where dynamic prognostication models have been developed.<xref ref-type="bibr" rid="article-22785.r26">[26]</xref>&#x000a0;</p>
        <p>Patients exhibiting worsening hepatic synthetic function require special considerations. Hepatic synthetic dysfunction is indicated by coagulopathy with prolonged&#x000a0;international normalized ratio, increasing creatinine, serum albumin levels below 3%, rising blood ammonia levels, and clinical signs of hepatic encephalopathy, necessitating prompt transfer to an intensive care unit, ideally at a liver transplant center. Patients should be classified using the United Network for Organ Sharing liver failure medical urgency classification (eg, MELD 1 or PELD 2) or by assigning a status (eg, 1A or 1B) for liver allocation based on country-specific guidelines and the availability of access to a transplant center.&#x000a0;Extrahepatic complications are managed accordingly.&#x000a0;</p>
        <p>In rare cases of severe relapse and cholestatic symptoms, patients have been given a short course of corticosteroids based on&#x000a0;anecdotal evidence and limited case reports, but randomized controlled trials are lacking.<xref ref-type="bibr" rid="article-22785.r27">[27]</xref>&#x000a0;Corticosteroids are also used for pure red cell aplasia caused by hepatitis A and have been tried in children with fulminant liver failure from hepatitis A.<xref ref-type="bibr" rid="article-22785.r28">[28]</xref><xref ref-type="bibr" rid="article-22785.r29">[29]</xref><xref ref-type="bibr" rid="article-22785.r30">[30]</xref><xref ref-type="bibr" rid="article-22785.r31">[31]</xref><xref ref-type="bibr" rid="article-22785.r32">[32]</xref><xref ref-type="bibr" rid="article-22785.r33">[33]</xref><xref ref-type="bibr" rid="article-22785.r34">[34]</xref><xref ref-type="bibr" rid="article-22785.r35">[35]</xref>&#x000a0;N-acetyl cysteine was not found to be useful.<xref ref-type="bibr" rid="article-22785.r36">[36]</xref></p>
      </sec>
      <sec id="article-22785.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses that should also be considered include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Other acute hepatitis viral infections (eg, hepatitis E virus and&#x000a0;hepatitis B virus)</p>
          </list-item>
          <list-item>
            <p>Non-hepatotropic viral infection (eg, dengue virus, cytomegalovirus infection, herpes simplex virus infection, Ebstein-Barr virus)</p>
          </list-item>
          <list-item>
            <p>Parasitic and zoonotic infectious diseases (eg, leptospiral and rickettsial infections, Q fever, malaria, and tropical fever syndromes)</p>
          </list-item>
          <list-item>
            <p>Drug-induced liver injury&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Autoimmune hepatitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ischemic hepatitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Alcohol-associated hepatitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Wilson disease</p>
          </list-item>
          <list-item>
            <p>Acute Budd-Chiari syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22785.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The outcomes for most patients with HAV are excellent. After an infection, long-term immunity is common, and unlike other viral hepatitis infections, recurrence of symptoms is rare. Death is rare but may occur in older individuals or those with underlying liver disease. In the United States, approximately 100 deaths from HAV occur every year. Liver transplant is rarely undertaken in children with fulminant disease. The most important prognostic factor is age; the older the individual, the more likely an adverse reaction or event may occur. Long-term sequelae are very rare.</p>
      </sec>
      <sec id="article-22785.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of HAV include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute liver failure and fulminant hepatitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acute liver injury&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prolonged cholestasis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acute-on-chronic liver failure in patients with preexisting hepatitis C virus infection or metabolic dysfunction associated steatotic liver disease</p>
          </list-item>
          <list-item>
            <p>Severe complications associated with HAV infection including pericarditis, renal failure, thrombocytopenia, acute pancreatitis, aplastic anemia, autoimmune hemolytic anemia, Guillain-Barr&#x000e9; syndrome, vasculitis, and arthritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22785.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>
<bold>Patient Education</bold>
</p>
        <p>Patient education efforts are tailored to specific at-risk populations, including persons who use injection and non-injection drugs, men who have sex with men, and individuals with chronic liver diseases, to address their unique vulnerabilities. Healthcare professionals should receive specialized training to enhance their ability to recognize HAV symptoms, comprehend transmission dynamics, and effectively educate patients. Travel-related education focuses on pre-travel vaccination and safe practices in high-endemicity areas. Management of the close contacts of patients with HAV involves education on postexposure prophylaxis and hygiene measures to prevent further transmission. During outbreaks, emphasis is placed on early identification, implementation of preventive measures, and coordinated vaccination campaigns.</p>
        <p>
<bold>Prevention Strategies</bold>
</p>
        <p>The cornerstone of preventing HAV transmission involves rigorous hygiene practices, emphasizing food and water safety, and advocating for widespread vaccination, particularly for high-risk groups and travelers to endemic regions. Preventing HAV infection requires public health measures such as improving hygiene, sanitation, socioeconomic conditions, immunoglobulin prophylaxis, and vaccination.<xref ref-type="bibr" rid="article-22785.r37">[37]</xref>&#x000a0;</p>
        <p>Data on HAV's persistence on surfaces, soil, water, food, and inactivation methods are limited. HAV can remain infectious on some foods for days and on frozen berries, feces, and soil for months. On surfaces, HAV can survive for months, influenced by temperature and humidity, and on hands for hours; however, thorough handwashing can remove the virus. HAV resists low pH, mild heat, pasteurization, and freezing. Personal hygiene and environmental sanitation are crucial to preventing HAV transmission through fecal contamination or personal contact. Monitoring HAV ribonucleic acid in sewage helps assess transmission risks.</p>
        <p>Universal pediatric vaccination is the most effective control measure in intermediate-risk regions. Before the advent of HAV vaccines, short-term pre-exposure and postexposure prophylaxis involved injecting intramuscular human immunoglobulin. Effective HAV vaccines have reduced immunoglobulin use due to their high cost, limited availability, and shorter protection duration compared to vaccines. Currently, the only indication of immunoglobulin is probably in individuals with hypersensitivity to vaccine components.&#x000a0;</p>
        <p>In the United States, vaccination against hepatitis A is available as inactivated, single-antigen vaccines (HAVRIX and VAQTA) or in combination with hepatitis B (TWINRIX). The Centers for Disease Control and Prevention recommends vaccination for children 12 months or older, travelers to endemic countries, men who have sex with men, persons with human immunodeficiency virus infection, persons who use injection and noninjection drugs, and individuals with occupational risk exposure or chronic liver disease. Standard adult dosing recommends administration of 2 doses of the vaccine 6 to 12 months apart. These vaccines are highly efficacious, with seroconversion rates approaching 100%. Live-attenuated HAV vaccines, licensed in China since 1992, have shown high efficacy and long-lasting immunity after a single dose. China's extensive infant vaccination program has significantly increased coverage and reduced hepatitis A incidence. Vaccination has proven effective in large-scale hepatitis A prevention, supporting its role in public health strategies.<xref ref-type="bibr" rid="article-22785.r38">[38]</xref></p>
      </sec>
      <sec id="article-22785.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective management of hepatitis A infection, especially in individuals at higher risk for adverse outcomes, requires a coordinated effort from an interprofessional healthcare team. Physicians, advanced clinicians, nurses, pharmacists, and other healthcare professionals must collaborate to deliver patient-centered care. Specialists and infectious disease experts are responsible for diagnosing and overseeing the treatment plan, while primary care clinicians ensure that patients receive appropriate supportive care.</p>
        <p>Pharmacists, advanced clinicians, and physicians are crucial in educating patients, particularly travelers to endemic areas, about the hepatitis A vaccine and preventive measures like proper hygiene and safe food practices. Nurses, especially those in infectious disease, must also counsel patients on necessary precautions to prevent the spread of the virus, such as adhering to strict enteric precautions and avoiding certain high-risk behaviors. Clear, interprofessional communication and care coordination are essential to enhance patient outcomes, safety, and overall team performance, ensuring that each professional's expertise contributes to comprehensive and effective care for patients with hepatitis A.</p>
      </sec>
      <sec id="article-22785.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22785&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22785">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/hepatitis-a/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22785">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22785/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22785">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22785.s16">
        <fig id="article-22785.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Hepatitis A Replication Cycle. The HAV replication cycle begins with virus attachment to hepatocytes via integrins and TIM1 receptors, followed by endosomal entry. In early endosomes, the virus dissociates from receptors, while in more acidic late endosomes capsid changes trigger RNA release into the cytoplasm. IRES-mediated translation produces a viral polyprotein, which undergoes proteolytic processing. Genome replication occurs on membrane structures, followed by virion assembly. New particles are released via multivesicular bodies (MVBs) as quasi-enveloped HAV (eHAV). Basolaterally released eHAV enters the bloodstream, while apically released eHAV enters the biliary tract, where bile salts remove the quasi-envelope, producing naked HAV (nHAV) for fecal shedding and transmission. This cycle encompasses key steps from attachment to transmission, highlighting HAV's unique quasi-enveloped state and bile salt-mediated envelope removal. Contributed by V Girish, MD&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HAV__life__cycle__x1x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22785.s17">
        <title>References</title>
        <ref id="article-22785.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Odenwald</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Viral hepatitis: Past, present, and future.</article-title>
            <source>World J Gastroenterol</source>
            <year>2022</year>
            <month>Apr</month>
            <day>14</day>
            <volume>28</volume>
            <issue>14</issue>
            <fpage>1405</fpage>
            <page-range>1405-1429</page-range>
            <pub-id pub-id-type="pmid">35582678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alberts</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bruisten</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Heijman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hogewoning</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rooijen</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Siedenburg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sonder</surname>
                <given-names>GJB</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis A incidence, seroprevalence, and vaccination decision among MSM in Amsterdam, the Netherlands.</article-title>
            <source>Vaccine</source>
            <year>2019</year>
            <month>May</month>
            <day>09</day>
            <volume>37</volume>
            <issue>21</issue>
            <fpage>2849</fpage>
            <page-range>2849-2856</page-range>
            <pub-id pub-id-type="pmid">30992222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Adherence to hepatitis A and hepatitis B multi-dose vaccination schedules among adults in the United Kingdom: a retrospective cohort study.</article-title>
            <source>BMC Public Health</source>
            <year>2019</year>
            <month>Apr</month>
            <day>15</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>404</fpage>
            <pub-id pub-id-type="pmid">30987613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brennan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sizemore</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mathieson</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wester</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Schaffner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Notes from the Field: Acute Hepatitis A Virus Infection Among Previously Vaccinated Persons with HIV Infection - Tennessee, 2018.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2019</year>
            <month>Apr</month>
            <day>12</day>
            <volume>68</volume>
            <issue>14</issue>
            <fpage>328</fpage>
            <page-range>328-329</page-range>
            <pub-id pub-id-type="pmid">30973852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hofmeister</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>McBee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Briscoe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomasson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Olaisen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Augustine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bamrah Morris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haddy</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Notes from the Field: Hepatitis A Outbreak Associated with Drug Use and Homelessness - West Virginia, 2018.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2019</year>
            <month>Apr</month>
            <day>12</day>
            <volume>68</volume>
            <issue>14</issue>
            <fpage>330</fpage>
            <page-range>330-331</page-range>
            <pub-id pub-id-type="pmid">30973849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feinstone</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kapikian</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Purceli</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness.</article-title>
            <source>Science</source>
            <year>1973</year>
            <month>Dec</month>
            <day>07</day>
            <volume>182</volume>
            <issue>4116</issue>
            <fpage>1026</fpage>
            <page-range>1026-8</page-range>
            <pub-id pub-id-type="pmid">4356028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <article-title>Hepatitis A virus infection.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2023</year>
            <month>Sep</month>
            <day>28</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <pub-id pub-id-type="pmid">37770501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sander</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Corman</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Lukashev</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Drexler</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Evolutionary Origins of Enteric Hepatitis Viruses.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2018</year>
            <month>Dec</month>
            <day>03</day>
            <volume>8</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">29610146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klevens</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sweet</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Cronquist</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khudyakov</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Spradling</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005-2007.</article-title>
            <source>Arch Intern Med</source>
            <year>2010</year>
            <month>Nov</month>
            <day>08</day>
            <volume>170</volume>
            <issue>20</issue>
            <fpage>1811</fpage>
            <page-range>1811-8</page-range>
            <pub-id pub-id-type="pmid">21059974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Davern</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hynan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>US Acute Liver Failure Study Group</collab>
            </person-group>
            <article-title>Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes.</article-title>
            <source>Hepatology</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>1589</fpage>
            <page-range>1589-97</page-range>
            <pub-id pub-id-type="pmid">17133489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shalimar</surname>
              </name>
              <name>
                <surname>Kedia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gunjan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sonika</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mahapatra</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Acute Liver Failure Due to Hepatitis E Virus Infection Is Associated with Better Survival than Other Etiologies in Indian Patients.</article-title>
            <source>Dig Dis Sci</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>1058</fpage>
            <page-range>1058-1066</page-range>
            <pub-id pub-id-type="pmid">28130708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Rawat</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Profile and outcome of first 109 cases of paediatric acute liver failure at a specialized paediatric liver unit in India.</article-title>
            <source>Liver Int</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>1508</fpage>
            <page-range>1508-1514</page-range>
            <pub-id pub-id-type="pmid">28111909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Natural History, Clinical Manifestations, and Pathogenesis of Hepatitis A.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>04</day>
            <volume>8</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">29440324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rivera-Serrano</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lemon</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Cell entry and release of quasi-enveloped human hepatitis viruses.</article-title>
            <source>Nat Rev Microbiol</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>573</fpage>
            <page-range>573-589</page-range>
            <pub-id pub-id-type="pmid">37185947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemon</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Van Damme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shouval</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention.</article-title>
            <source>J Hepatol</source>
            <year>2017</year>
            <month>Sep</month>
            <day>05</day>
            <pub-id pub-id-type="pmid">28887164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vallbracht</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fleischer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>FW</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis A: hepatotropism and influence on myelopoiesis.</article-title>
            <source>Intervirology</source>
            <year>1993</year>
            <volume>35</volume>
            <issue>1-4</issue>
            <fpage>133</fpage>
            <page-range>133-9</page-range>
            <pub-id pub-id-type="pmid">8407240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanford</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lemon</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis.</article-title>
            <source>ILAR J</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-189</page-range>
            <pub-id pub-id-type="pmid">29045731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misumi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Cullen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lemon</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Whitmire</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>T cells protect against hepatitis A virus infection and limit infection-induced&#x000a0;liver injury.</article-title>
            <source>J Hepatol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1323</fpage>
            <page-range>1323-1334</page-range>
            <pub-id pub-id-type="pmid">34331968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeong</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis A: clinical manifestations and management.</article-title>
            <source>Intervirology</source>
            <year>2010</year>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-9</page-range>
            <pub-id pub-id-type="pmid">20068336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okuno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katsuma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogasawara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okanoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takino</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pathology of acute hepatitis A in humans. Comparison with acute hepatitis B.</article-title>
            <source>Am J Clin Pathol</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-9</page-range>
            <pub-id pub-id-type="pmid">6695857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Usuda</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kaneoka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Inami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tsuge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sakurai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsubara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimozawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hotchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Osugi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Katou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mishima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takami</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Komatsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sugita</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Current perspectives of viral hepatitis.</article-title>
            <source>World J Gastroenterol</source>
            <year>2024</year>
            <month>May</month>
            <day>14</day>
            <volume>30</volume>
            <issue>18</issue>
            <fpage>2402</fpage>
            <page-range>2402-2417</page-range>
            <pub-id pub-id-type="pmid">38764770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemon</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis A: Current view of an ancient disease.</article-title>
            <source>J Hepatol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>243</fpage>
            <page-range>243-244</page-range>
            <pub-id pub-id-type="pmid">35513903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abutaleb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kottilil</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis A: Epidemiology, Natural History, Unusual Clinical Manifestations, and Prevention.</article-title>
            <source>Gastroenterol Clin North Am</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-199</page-range>
            <pub-id pub-id-type="pmid">32389358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elinav</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ben-Dov</surname>
                <given-names>IZ</given-names>
              </name>
              <name>
                <surname>Shapira</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Daudi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shouval</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor.</article-title>
            <source>Gastroenterology</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>130</volume>
            <issue>4</issue>
            <fpage>1129</fpage>
            <page-range>1129-34</page-range>
            <pub-id pub-id-type="pmid">16618407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terrault</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Jourdain</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Viral hepatitis and pregnancy.</article-title>
            <source>Nat Rev Gastroenterol Hepatol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-130</page-range>
            <pub-id pub-id-type="pmid">33046891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shalimar</surname>
              </name>
              <name>
                <surname>Sonika</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kedia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahapatra</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Gunjan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Dynamic Changes Among Various Prognostic Scores in Viral Hepatitis-Related Acute Liver Failure.</article-title>
            <source>Ann Hepatol</source>
            <year>2018</year>
            <season>May-June</season>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-412</page-range>
            <pub-id pub-id-type="pmid">29735790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoon</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Yim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Clinical courses after administration of oral corticosteroids in patients with severely cholestatic acute hepatitis A; three cases.</article-title>
            <source>Korean J Hepatol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>329</fpage>
            <page-range>329-33</page-range>
            <pub-id pub-id-type="pmid">20924218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zakaria</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>El-Araby</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Elbadry</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Sira</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Abd-Alaaty</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Goda</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Eltaras</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Abou-Zeinah</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sira</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Steroid therapy in children with fulminant hepatitis A.</article-title>
            <source>J Viral Hepat</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>853</fpage>
            <page-range>853-859</page-range>
            <pub-id pub-id-type="pmid">29397017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darchis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Colombel</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Cortot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Devienne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bauters</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paris</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Pure red cell aplasia during the course of virus A hepatitis.</article-title>
            <source>Gastroenterol Clin Biol</source>
            <year>1990</year>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>1027</fpage>
            <pub-id pub-id-type="pmid">2127029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Marcelin</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Virk</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pre-travel counseling for immunocompromised travelers: A 12-year single-center retrospective review.</article-title>
            <source>Infect Dis Health</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-22</page-range>
            <pub-id pub-id-type="pmid">30541695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Link-Gelles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hofmeister</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Schillie</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2018</year>
            <month>Nov</month>
            <day>02</day>
            <volume>67</volume>
            <issue>43</issue>
            <fpage>1216</fpage>
            <page-range>1216-1220</page-range>
            <pub-id pub-id-type="pmid">30383742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gervasi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Biticchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zaratti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Epidemics of Hepatitis A and opportunities for vaccination: a focus on the category of men who practice sex with men (MSM)].</article-title>
            <source>Ig Sanita Pubbl</source>
            <year>2018</year>
            <season>May-Jun</season>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>295</fpage>
            <page-range>295-304</page-range>
            <pub-id pub-id-type="pmid">30235469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waszczuk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Waszczuk</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Szenborn</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Can we better protect patients with inflammatory bowel disease against infections - patient attitude and personal immunization knowledge.</article-title>
            <source>Acta Gastroenterol Belg</source>
            <year>2018</year>
            <season>Apr-Jun</season>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-261</page-range>
            <pub-id pub-id-type="pmid">30024696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Leary</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Kimberlin</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Update From the Advisory Committee on Immunization Practices.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2018</year>
            <month>Aug</month>
            <day>17</day>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-187</page-range>
            <pub-id pub-id-type="pmid">29961833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Crosby</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gratzer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Meites</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Disclosure of Sexual Behavior Is Significantly Associated With Receiving a Panel of Health Care Services Recommended for Men Who Have Sex With Men.</article-title>
            <source>Sex Transm Dis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>12</issue>
            <fpage>803</fpage>
            <page-range>803-807</page-range>
            <pub-id pub-id-type="pmid">29944645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunduz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Karabay</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tamer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ozaras</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabak</surname>
                <given-names>OF</given-names>
              </name>
            </person-group>
            <article-title>N-acetyl cysteine therapy in acute viral hepatitis.</article-title>
            <source>World J Gastroenterol</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>12</issue>
            <fpage>2698</fpage>
            <page-range>2698-700</page-range>
            <pub-id pub-id-type="pmid">14669316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wetten</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Viral hepatitis in 2021: The challenges remaining and how we should tackle them.</article-title>
            <source>World J Gastroenterol</source>
            <year>2022</year>
            <month>Jan</month>
            <day>07</day>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-95</page-range>
            <pub-id pub-id-type="pmid">35125820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22785.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Migueres</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lhomme</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Izopet</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.</article-title>
            <source>Viruses</source>
            <year>2021</year>
            <month>Sep</month>
            <day>22</day>
            <volume>13</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">34696330</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
